🚀 The Mega-Merger That Wasn’t
Early August saw the Financial Times report that AstraZeneca and Bristol Myers Squibb (BMS) were in “early-stage talks” about a potential $400 billion merger. The market reaction was immediate: AstraZeneca shares dropped nearly 9% in London, while BMS shares rose in the US. However, within days, a senior source told Reuters there were “no discussions” ongoing and “there never was a deal to be done,” effectively squashing the rumor and sending AstraZeneca shares back up.
💊 GLP-1 & Obesity Advances
Eli Lilly’s Oral Pill Gets UK Approval: The MHRA approved Lilly’s orforglipron (Foundayo) for both weight loss and type 2 diabetes, bringing it into direct competition with Novo Nordisk’s oral Wegovy. NICE guidance for NHS use is expected in November.
· Novo Nordisk’s Mystery Candidate: Novo registered a Phase I trial for NNC0721-8060, an undisclosed obesity candidate that will be tested against its own semaglutide (Wegovy). The trial is set to begin in August 2026, with primary completion by September 2027.
· CagriSema Trial Results (Update): While the full study was published in June, the data from the REIMAGINE 2 trial showed that Novo Nordisk’s CagriSema (cagrilintide + semaglutide) was superior to semaglutide alone for glycemic control in type 2 diabetes, supporting its potential as a combination therapy.
🔬 Breakthroughs in Oncology & mRNA
mRNA Melanoma Vaccine Success: Moderna and Merck published positive Phase 3 data for their personalized mRNA melanoma vaccine intismeran (with Keytruda), which met its primary endpoint. This landmark milestone validates mRNA technology in precision oncology and extends the reach of Keytruda. Moderna also secured US approval for its first standalone mRNA flu vaccine this month.
📜 Key Regulatory Approvals & Filings
· Novel FDA Approvals: In a signal toward convenience-driven care, the FDA approved several first-in-class therapies:
· Orca-T (Tregzi): First therapy built on purified regulatory T cells for matched donor stem cell transplants.
· Enlicitide (Lipfendra): First oral PCSK9 inhibitor for lowering LDL-C cholesterol.
· Atacicept (Trutakna): First dual BAFF/APRIL inhibitor for IgA nephropathy (accelerated approval).
· Bulevirtide (Hepcludex): Gilead secured FDA approval for treating chronic hepatitis D, making it the first FDA-approved drug for this severe form of viral hepatitis.
· Clinical Trial Approvals: Heidelberg Pharma and Huadong Medicine received NMPA approval in China for a Phase Ib/II trial of pamlectabart tismanitin (HDP-101), a BCMA-targeting ADC, for relapsed/refractory multiple myeloma. China’s NMPA also approved a clinical trial for Yipinhong’s novel drug APH03867.
🏭 Industry & Regulatory Updates
· Aurobindo Pharma USFDA Observations: The US FDA concluded a routine inspection at Aurobindo’s subsidiary Lannett Company LLC with four procedural observations, as well as one observation at AuroPeptides Ltd. The company stated the observations were procedural and will respond within the stipulated timeline.
· India’s Pharma Export Pact: The Central Bureau of Narcotics and PHARMEXCIL signed an MoU to boost pharmaceutical exports while ensuring regulatory oversight, recognizing India’s position as a leading global supplier of APIs and formulations.
Disclaimer: This summary reflects news reported during August 2026. The status of clinical trials, regulatory approvals, and M&A deals is subject to change as new information becomes available.
